12 Years of Excellence: South Korea’s Biggest Biologics Manufacturing Conference
The 13th Edition of Biologics Manufacturing Korea 2024 continues to uphold its status as Korea's premier bioprocessing-focused conference, offering a targeted platform for regional biopharmaceutical industry stakeholders to foster strategic collaboration, gain exposure to cutting-edge manufacturing technologies, and share knowledge. This year's agenda is meticulously crafted to showcase success stories from Korea's leading biopharmas, coupled with insights from international biopharmas and major pharmaceutical companies.
The agenda for this year's Biologics Manufacturing Korea 2024 conference is thoughtfully designed to encapsulate the dynamic landscape of the South Korea biologics manufacturing market. It encompasses crucial themes such as upstream processing with a focus on high-throughput cell line development and cell culture, downstream processing involving product concentration and purification by chromatography, analytics and quality assurance, automation, Bioprocessing 4.0, and the digitalization landscape. The conference also features a dedicated showcase for Contract Manufacturing Organizations (CMOs) and Contract Development and Manufacturing Organizations (CDMOs), emphasizing their contributions. Furthermore, the inclusion of sessions on Cell & Gene Therapy Manufacturing Excellence and a specific Case Study Session in this transformative field, along with discussions on facility design and capacity planning, solidifies the conference as a comprehensive platform for knowledge exchange and collaboration in the biologics manufacturing sector.
Building upon the success of previous editions, the conference aims to provide a comprehensive view of the rapidly evolving landscape of biologics manufacturing. Participants can look forward to engaging sessions, networking opportunities, and exposure to the latest industry trends. Join us for BMK 2024 to stay at the forefront of the biopharmaceutical industry's advancements and contribute to the collective knowledge sharing within the bioprocessing community.
This session involves a discussion among industry leaders to analyze the present status and future prospects of biologics manufacturing in South Korea, including market trends, regulatory landscape, and potential growth opportunities.
Explores advanced approaches and technologies for high-throughput cell line development and optimization of cell culture conditions to increase productivity and accelerate biologics manufacturing processes.
Explores techniques and methodologies for product concentration and purification using chromatography in downstream bioprocessing, emphasizing optimization strategies and emerging trends.
Explores the role of analytics and quality assurance in biopharmaceutical manufacturing, including process analytics, data integrity, and regulatory compliance to ensure product safety and efficacy.
This session explores the integration of automation, bioprocessing 4.0 technologies, and digitalization in biopharmaceutical manufacturing, highlighting advancements in process optimization, data analytics, and real-time monitoring for improved efficiency and quality.
Highlights the capabilities and offerings of contract manufacturing organizations (CMOs) and contract development and manufacturing organizations (CDMOs) in supporting biologics and/or cell and gene therapy production, showcasing their expertise in process development, scale-up, and commercialization.
Examines best practices and advancements in cell and gene therapy manufacturing, covering topics such as vector production, gene editing technologies, and process scale-up for commercialization.
Covers best practices and strategies for transferring technology from research to manufacturing scale and scaling up production processes efficiently while maintaining product quality and regulatory compliance.
Discusses considerations and strategies for fill-finish operations, facility design, and capacity planning in biopharmaceutical manufacturing to meet growing demand and ensure operational efficiency.
Standard Price
SGD 2,495
Late Kate
SGD 2,795
*END-USER PRICING IS APPLICABLE to :
Company Profiles: Asian and International Biopharma, BIG Pharmas, Asian Academic & Research Institutes.
Job Profiles: Manufacturing, Bioprocessing, Production, USP, DSP, Operations, Site Heads, Drug Substance and Product Manufacturing, Process Development, Quality, Analytics and other related technical designations.
Standard Price
SGD 4,395
Late Kate
SGD 4,695
*SOLUTION PROVIDER PRICING IS APPLICABLE to
Company Profile: Technology and Solutions Provider, Asian/International Biopharma, BIG Pharmas, CMO’s, Asian Academic/Research Institutes.
Job Profiles: Business Development, Marketing & Sales
Standard Price
SGD 2,495
Late Kate
SGD 2,795
*END-USER PRICING IS APPLICABLE to :
Company Profiles: Asian and International Biopharma, BIG Pharmas, Asian Academic & Research Institutes.
Job Profiles: Manufacturing, Bioprocessing, Production, USP, DSP, Operations, Site Heads, Drug Substance and Product Manufacturing, Process Development, Quality, Analytics and other related technical designations.
Standard Price
SGD 4,395
Late Kate
SGD 4,695
*SOLUTION PROVIDER PRICING IS APPLICABLE to
Company Profile: Technology and Solutions Provider, Asian/International Biopharma, BIG Pharmas, CMO’s, Asian Academic/Research Institutes.
Job Profiles: Business Development, Marketing & Sales
IVI’s laboratory science division designs new vaccines, improves the formulation of existing vaccines, conducts preclinical studies, evaluates the safety and performance of promising vaccine candidates, develops technologies to support vaccine clinical testing in human, optimizes production processes in advance of industrial-level scale-up, and transfers vaccine technology to manufacturers. Technology transfer takes place on the condition that selected manufacturers produce high-quality vaccines at low cost in a country with a functional National Regulatory Authority accredited by WHO.
Our laboratories in Seoul are equipped with microbiological, immunological, and genomic containment as well as BSL-3, BSL-2, GCLP labs and animal facilities. Our teams specialize in molecular biology, microbial genetics, bioinformatics, and immunology.
6:00 PM - 7:30 PM
13th August 2024
Songdo Convensia Convention Center, Incheon, South Korea
IMAPAC is the go-to holistic producer of live events, biopharma data and digital marketing solutions for the global biopharmaceutical industry.
© 2024 Imapac. All rights reserved. Trade marks are owned by or licensed to imapac.
12 Years of Excellence: South Korea’s Biggest Biologics Manufacturing Conference
IMAPAC requires your contact information to reach out to you about our products and services. You can unsubscribe from these communications at any time. For details on how to unsubscribe and to learn more about our privacy practices and our commitment to protecting your privacy, please review our Privacy Policy.
IMAPAC requires your contact information to reach out to you about our products and services. You can unsubscribe from these communications at any time. For details on how to unsubscribe and to learn more about our privacy practices and our commitment to protecting your privacy, please review our Privacy Policy.